Form 4: Biocryst Pharmaceuticals Director Acquires Shares

Biocryst Pharmaceuticals Director Jon P. Stonehouse acquired 631 shares of common stock through a retainer compensation plan.

Summary

• Jon P. Stonehouse, a Director at Biocryst Pharmaceuticals Inc. (BCRX), acquired 631 shares of common stock on May 29, 2026.
• These shares were issued in lieu of 50% of his quarterly Board Member retainer, which amounts to $11,250.
• The acquisition price for these shares was $8.91 per share.
• Following this transaction, Stonehouse beneficially owns 1,324,481 shares of common stock.
• Additional holdings include 40,000 shares held indirectly by his wife as co-trustee of the Caroline Stonehouse Irrevocable Trust, and another 40,000 shares held indirectly by his wife as co-trustee of the Samuel Stonehouse Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine compensation-related insider transaction rather than a significant strategic event or financial performance indicator.

Positives

• Director compensation structure includes equity, aligning management interests with shareholders.
• The director continues to hold a significant number of shares, indicating confidence in the company.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that the issuance of equity in lieu of cash compensation is a common practice in the biopharmaceutical industry, particularly for directors, to conserve cash and align incentives.

Stakeholder Impact

• Shareholders: The transaction reflects a standard compensation practice, potentially aligning director interests with long-term company value through equity ownership.

Key Dates

Keywords

Biocryst Pharmaceuticals, BCRX, Form 4, Insider Transaction, Director Compensation, Common Stock, Equity